aluates Reports

$ 0.0

Automative

Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-1Q18062

BUY CHAPTERS

Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2024

Code: QYRE-Auto-1Q18062

Report

August 2024

Pages:98

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Companies

ACADIA Pharmaceuticals Inc.

Kyowa Kirin

Supernus Pharmaceuticals

UCB

Sumitomo Pharma

Biogen

Eisai Co Ltd

Eli Lilly

Green Valley

Novartis

Bristol–Myers Squibb

Janssen

Sanofi

Roche

Neurocrine

Lundbeck

TEVA

Targeted Drugs for Neurodegenerative Diseases Market

The global Targeted Drugs for Neurodegenerative Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Targeted Drugs for Neurodegenerative Diseases in Parkinson's Disease (PD) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Targeted Drugs for Neurodegenerative Diseases include Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Neurodegenerative Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Neurodegenerative Diseases.

The Targeted Drugs for Neurodegenerative Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Neurodegenerative Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Targeted Drugs for Neurodegenerative Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Targeted Drugs for Neurodegenerative Diseases Market Report

Report Metric	Details
Report Name	Targeted Drugs for Neurodegenerative Diseases Market
Segment by Type	Injection Oral
Segment by Application	Parkinson's Disease (PD) Alzheimer's Disease (AD) Huntington's Disease (HD) Tardive Dyskinesia (TD) Multiple Sclerosis (MS)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, Bristol-Myers Squibb, Janssen, Sanofi, Roche, Neurocrine, Lundbeck, Teva
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Neurodegenerative Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The main players in the Targeted Drugs for Neurodegenerative Diseases Market are Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, Bristol-Myers Squibb, Janssen, Sanofi, Roche, Neurocrine, Lundbeck, Teva

What are the Application segmentation covered in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The Applications covered in the Targeted Drugs for Neurodegenerative Diseases Market report are Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), Tardive Dyskinesia (TD), Multiple Sclerosis (MS)

What are the Type segmentation covered in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The Types covered in the Targeted Drugs for Neurodegenerative Diseases Market report are Injection, Oral

Recommended Reports

Alzheimer's Disease

Neurodegenerative Disorders

Related Neurological

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Injection

1.2.3 Oral

1.3 Market by Application

1.3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Parkinson's Disease (PD)

1.3.3 Alzheimer's Disease (AD)

1.3.4 Huntington's Disease (HD)

1.3.5 Tardive Dyskinesia (TD)

1.3.6 Multiple Sclerosis (MS)

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Perspective (2019-2030)

2.2 Global Targeted Drugs for Neurodegenerative Diseases Growth Trends by Region

2.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Region (2019-2024)

2.2.3 Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (2025-2030)

2.3 Targeted Drugs for Neurodegenerative Diseases Market Dynamics

2.3.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends

2.3.2 Targeted Drugs for Neurodegenerative Diseases Market Drivers

2.3.3 Targeted Drugs for Neurodegenerative Diseases Market Challenges

2.3.4 Targeted Drugs for Neurodegenerative Diseases Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue

3.1.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue (2019-2024)

3.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2019-2024)

3.2 Global Targeted Drugs for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Targeted Drugs for Neurodegenerative Diseases Revenue

3.4 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio

3.4.1 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Neurodegenerative Diseases Revenue in 2023

3.5 Global Key Players of Targeted Drugs for Neurodegenerative Diseases Head office and Area Served

3.6 Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Product and Application

3.7 Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Type

4.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Type (2019-2024)

4.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (2025-2030)

5 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Application

5.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Application (2019-2024)

5.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size (2019-2030)

6.2 North America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

6.4 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size (2019-2030)

7.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

7.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size (2019-2030)

8.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024)

8.4 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size (2019-2030)

9.2 Latin America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

9.4 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size (2019-2030)

10.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

10.4 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Acadia Pharmaceuticals Inc.

11.1.1 Acadia Pharmaceuticals Inc. Company Details

11.1.2 Acadia Pharmaceuticals Inc. Business Overview

11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Introduction

11.1.4 Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.1.5 Acadia Pharmaceuticals Inc. Recent Development

11.2 Kyowa Kirin

11.2.1 Kyowa Kirin Company Details

11.2.2 Kyowa Kirin Business Overview

11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Introduction

11.2.4 Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.2.5 Kyowa Kirin Recent Development

11.3 Supernus Pharmaceuticals

11.3.1 Supernus Pharmaceuticals Company Details

11.3.2 Supernus Pharmaceuticals Business Overview

11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Introduction

11.3.4 Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.3.5 Supernus Pharmaceuticals Recent Development

11.4 UCB

11.4.1 UCB Company Details

11.4.2 UCB Business Overview

11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Introduction

11.4.4 UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.4.5 UCB Recent Development

11.5 Sumitomo Pharma

11.5.1 Sumitomo Pharma Company Details

11.5.2 Sumitomo Pharma Business Overview

11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Introduction

11.5.4 Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.5.5 Sumitomo Pharma Recent Development

11.6 Biogen

11.6.1 Biogen Company Details

11.6.2 Biogen Business Overview

11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Introduction

11.6.4 Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.6.5 Biogen Recent Development

11.7 Eisai Inc.

11.7.1 Eisai Inc. Company Details

11.7.2 Eisai Inc. Business Overview

11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Introduction

11.7.4 Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.7.5 Eisai Inc. Recent Development

11.8 Eli Lilly

11.8.1 Eli Lilly Company Details

11.8.2 Eli Lilly Business Overview

11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Introduction

11.8.4 Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.8.5 Eli Lilly Recent Development

11.9 Green Valley

11.9.1 Green Valley Company Details

11.9.2 Green Valley Business Overview

11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Introduction

11.9.4 Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.9.5 Green Valley Recent Development

11.10 NOVARTIS

11.10.1 NOVARTIS Company Details

11.10.2 NOVARTIS Business Overview

11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Introduction

11.10.4 NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.10.5 NOVARTIS Recent Development

11.11 Bristol-Myers Squibb

11.11.1 Bristol-Myers Squibb Company Details

11.11.2 Bristol-Myers Squibb Business Overview

11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Introduction

11.11.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.11.5 Bristol-Myers Squibb Recent Development

11.12 Janssen

11.12.1 Janssen Company Details

11.12.2 Janssen Business Overview

11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Introduction

11.12.4 Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.12.5 Janssen Recent Development

11.13 Sanofi

11.13.1 Sanofi Company Details

11.13.2 Sanofi Business Overview

11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Introduction

11.13.4 Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.13.5 Sanofi Recent Development

11.14 Roche

11.14.1 Roche Company Details

11.14.2 Roche Business Overview

11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Introduction

11.14.4 Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.14.5 Roche Recent Development

11.15 Neurocrine

11.15.1 Neurocrine Company Details

11.15.2 Neurocrine Business Overview

11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Introduction

11.15.4 Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.15.5 Neurocrine Recent Development

11.16 Lundbeck

11.16.1 Lundbeck Company Details

11.16.2 Lundbeck Business Overview

11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Introduction

11.16.4 Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.16.5 Lundbeck Recent Development

11.17 Teva

11.17.1 Teva Company Details

11.17.2 Teva Business Overview

11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Introduction

11.17.4 Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

11.17.5 Teva Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Companies

ACADIA Pharmaceuticals Inc.

Kyowa Kirin

Supernus Pharmaceuticals

UCB

Sumitomo Pharma

Biogen

Eisai Co Ltd

Eli Lilly

Green Valley

Novartis

Bristol–Myers Squibb

Janssen

Sanofi

Roche

Neurocrine

Lundbeck

TEVA

List of Tables

Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Injection

Table 3. Key Players of Oral

Table 4. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2019-2024)

Table 8. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2025-2030)

Table 10. Targeted Drugs for Neurodegenerative Diseases Market Trends

Table 11. Targeted Drugs for Neurodegenerative Diseases Market Drivers

Table 12. Targeted Drugs for Neurodegenerative Diseases Market Challenges

Table 13. Targeted Drugs for Neurodegenerative Diseases Market Restraints

Table 14. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Players (2019-2024)

Table 16. Global Top Targeted Drugs for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Neurodegenerative Diseases as of 2023)

Table 17. Ranking of Global Top Targeted Drugs for Neurodegenerative Diseases Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Targeted Drugs for Neurodegenerative Diseases Revenue (CR5 and HHI) & (2019-2024)

Table 19. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Headquarters and Area Served

Table 20. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Product and Application

Table 21. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2019-2024)

Table 25. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2025-2030)

Table 27. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2019-2024)

Table 29. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2025-2030)

Table 31. North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2025-2030) & (US$ Million)

Table 46. Acadia Pharmaceuticals Inc. Company Details

Table 47. Acadia Pharmaceuticals Inc. Business Overview

Table 48. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product

Table 49. Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 50. Acadia Pharmaceuticals Inc. Recent Development

Table 51. Kyowa Kirin Company Details

Table 52. Kyowa Kirin Business Overview

Table 53. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product

Table 54. Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 55. Kyowa Kirin Recent Development

Table 56. Supernus Pharmaceuticals Company Details

Table 57. Supernus Pharmaceuticals Business Overview

Table 58. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product

Table 59. Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 60. Supernus Pharmaceuticals Recent Development

Table 61. UCB Company Details

Table 62. UCB Business Overview

Table 63. UCB Targeted Drugs for Neurodegenerative Diseases Product

Table 64. UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 65. UCB Recent Development

Table 66. Sumitomo Pharma Company Details

Table 67. Sumitomo Pharma Business Overview

Table 68. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product

Table 69. Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 70. Sumitomo Pharma Recent Development

Table 71. Biogen Company Details

Table 72. Biogen Business Overview

Table 73. Biogen Targeted Drugs for Neurodegenerative Diseases Product

Table 74. Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 75. Biogen Recent Development

Table 76. Eisai Inc. Company Details

Table 77. Eisai Inc. Business Overview

Table 78. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product

Table 79. Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 80. Eisai Inc. Recent Development

Table 81. Eli Lilly Company Details

Table 82. Eli Lilly Business Overview

Table 83. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product

Table 84. Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 85. Eli Lilly Recent Development

Table 86. Green Valley Company Details

Table 87. Green Valley Business Overview

Table 88. Green Valley Targeted Drugs for Neurodegenerative Diseases Product

Table 89. Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 90. Green Valley Recent Development

Table 91. NOVARTIS Company Details

Table 92. NOVARTIS Business Overview

Table 93. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product

Table 94. NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 95. NOVARTIS Recent Development

Table 96. Bristol-Myers Squibb Company Details

Table 97. Bristol-Myers Squibb Business Overview

Table 98. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product

Table 99. Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 100. Bristol-Myers Squibb Recent Development

Table 101. Janssen Company Details

Table 102. Janssen Business Overview

Table 103. Janssen Targeted Drugs for Neurodegenerative Diseases Product

Table 104. Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 105. Janssen Recent Development

Table 106. Sanofi Company Details

Table 107. Sanofi Business Overview

Table 108. Sanofi Targeted Drugs for Neurodegenerative Diseases Product

Table 109. Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 110. Sanofi Recent Development

Table 111. Roche Company Details

Table 112. Roche Business Overview

Table 113. Roche Targeted Drugs for Neurodegenerative Diseases Product

Table 114. Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 115. Roche Recent Development

Table 116. Neurocrine Company Details

Table 117. Neurocrine Business Overview

Table 118. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product

Table 119. Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 120. Neurocrine Recent Development

Table 121. Lundbeck Company Details

Table 122. Lundbeck Business Overview

Table 123. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product

Table 124. Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 125. Lundbeck Recent Development

Table 126. Teva Company Details

Table 127. Teva Business Overview

Table 128. Teva Targeted Drugs for Neurodegenerative Diseases Product

Table 129. Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024) & (US$ Million)

Table 130. Teva Recent Development

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

Table 134. Authors List of This Report

List of Figures

Figure 1. Targeted Drugs for Neurodegenerative Diseases Picture

Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Type: 2023 VS 2030

Figure 4. Injection Features

Figure 5. Oral Features

Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2024-2030) & (US$ Million)

Figure 7. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Application: 2023 VS 2030

Figure 8. Parkinson's Disease (PD) Case Studies

Figure 9. Alzheimer's Disease (AD) Case Studies

Figure 10. Huntington's Disease (HD) Case Studies

Figure 11. Tardive Dyskinesia (TD) Case Studies

Figure 12. Multiple Sclerosis (MS) Case Studies

Figure 13. Targeted Drugs for Neurodegenerative Diseases Report Years Considered

Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region: 2023 VS 2030

Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Players in 2023

Figure 18. Global Top Targeted Drugs for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Neurodegenerative Diseases as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Targeted Drugs for Neurodegenerative Diseases Revenue in 2023

Figure 20. North America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2019-2030)

Figure 22. United States Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2019-2030)

Figure 26. Germany Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2019-2030)

Figure 34. China Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2019-2030)

Figure 42. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2019-2030)

Figure 46. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. UAE Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 50. Kyowa Kirin Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 51. Supernus Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 52. UCB Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 53. Sumitomo Pharma Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 54. Biogen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 55. Eisai Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 56. Eli Lilly Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 57. Green Valley Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 58. NOVARTIS Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 60. Janssen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 61. Sanofi Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 62. Roche Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 63. Neurocrine Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 64. Lundbeck Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 65. Teva Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2019-2024)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Targeted Drugs for Alzheimer s Disease Market Research Report 2024

Global Neurodegenerative Disorder Therapeutics Market Research Report 2024

Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neurodegenerative Disease Treatment Market Research Report 2024

Global Targeted Drugs for Huntington s Disease Market Research Report 2024

Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drugs for Multiple Sclerosis Market Research Report 2024

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Neuroregeneration Therapy Market Research Report 2024

Global Neurologic Disorder Treatment Drug Market Research Report 2024

Global Neurological Biomarkers for Alzheimer s and Parkinson s Diseases Market Research Report 2025

Global Targeted Delivery Drugs Market Research Report 2024

Global Targeted Protein Degradation Drug Market Research Report 2024

Central Nervous System Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Parkinson Treatment Drug Market Research Report 2025

Global Cardiometabolic Disease Drug Market Research Report 2024

Global Alzheimer s Drugs Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions